How Green Is Your Selective Serotonin Reuptake Inhibitors Market?

Posted by sarahbennu on September 30th, 2019

Selective serotonin reuptake inhibitors are drugs that elevate the extracellular levels of serotonin, a neurotransmitter, by inhibiting its uptake in the presynaptic cells. Hence, these drugs are used for the treatment of severe or persistent depression. 

Looking for more information on this market? Request a free sample report

The geriatric population is more likely to develop mental disorders when compared to the adult population. As per the CDC, it is estimated that 80% of the geriatric population has at least one chronic illness, and 50% have two or more. The prevalence rate of depression in geriatric population in the US ranges from less than 1% to 5% and may rise to 13.5% in those who require home healthcare services and 11.5% in older adults admitted in hospitals. 

The geriatric population living with depression are generally misdiagnosed as healthcare professionals see depression as a natural reaction or change in life that may occur in people as they age. However, factors such as increased awareness about self-health in patients and the availability of efficacious antidepressants such as SSRIs can increase the chances that a higher percentage of the geriatric population will opt for SSRI treatment regimes. Hence, the growing geriatric population will drive the growth of the global selective serotonin reuptake inhibitors market at a CAGR of 3.53% during the forecast period. 

Top Selective Serotonin Reuptake Inhibitors (SSRIs) Companies Covered in this Market Research Report

The market is fragmented. This report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. This will help clients in improving their market positions. It also provides a detailed analysis of the upcoming selective serotonin reuptake inhibitors market trends and challenges and how they will influence market growth. This will help companies in creating effective strategies to leverage the upcoming market growth opportunities.

The report offers a detailed analysis of a few leading selective serotonin reuptake inhibitors companies, including:

Allergan Plc

Eli Lilly and Co.

GlaxoSmithKline Plc

H. Lundbeck AS

Pfizer Inc.

Browse Full Report - http://bit.ly/2n00ED7